Collegium Pharmaceutical, Inc. COLL R2KR3KPHARMA
Company Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Why Investors Should Care
Generates a return on equity of 17.6%, reflecting efficient use of shareholder capital.
Net profit has compounded at 18.6% per year over the last five years.
Revenue has grown at a 97.5% CAGR over the past five years.
Trades at a P/E of 18.5, below the sector median of 25.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $780.57M (+23.6% YoY); net profit $62.87M.
- Trailing 12 Months Year-on-year growth — revenue +6.3%, earnings -9.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 97.5%, profit CAGR 18.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 97.45% |
| 1 Year: | 6.30% |
Compounded Profit Growth
| 5 Years: | 18.64% |
| 1 Year: | -9.13% |
Stock Price Performance
| 1 Year: | -37.85% |
| 6 Months: | -36.90% |
| 3 Months: | -29.51% |
| 1 Month: | -19.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)24.46 · Oversold
P/E of 18.53 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 97.5% over 5 years.
- Profit CAGR of 18.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 52.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 24 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COLL Collegium Pharmaceutical, Inc. R2KR3KPHARMA | 23.53 | 18.53 | $763.17M | 0.00% | 14.76% | 17.61% | 97.45% | 18.64% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 2.17M | 3.56M | 11.95M | 10.79M | 63.75M | 73.06M | 70.18M | 73.43M | 74.52M | 75.04M | 72.94M | 74.20M | 76.51M | 78.06M | 79.18M | 76.27M | 87.72M | 82.94M | 78.84M | 27.36M | 83.75M | 123.55M | 127.01M | 129.62M | 144.77M | 135.55M | 136.71M | 149.75M | 144.92M | 145.28M | - | - | 177.76M | 188.00M | 209.36M | 205.45M | 193.52M | 199.88M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.43M | 79.62M | 80.19M | 77.07M | 76.27M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 25.35M | 26.39M | 26.19M | 25.11M | 38.99M | 48.36M | 48.19M | 44.29M | 55.60M | 50.24M | 46.11M | -1.33M | 48.50M | 52.36M | 58.84M | 49.79M | 77.40M | 73.83M | 80.31M | 94.63M | 91.46M | 90.81M | - | - | 97.32M | 108.38M | 129.17M | 128.38M | 117.25M | 110.29M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.42M | 73.64M | 67.10M | 67.64M | 86.35M | - |
| Operating Income | -26.44M | -27.58M | -23.18M | -21.26M | -13.43M | -17.58M | -13.21M | -7.29M | -11.19M | 11.00M | -9.99M | -5.01M | -6.38M | -2.37M | 5.06M | 16.55M | 19.63M | 15.00M | 21.19M | 16.41M | 14.15M | -34.12M | -10.02M | 11.11M | 20.47M | 11.76M | 24.63M | 35.63M | 45.01M | 61.69M | 49.47M | 47.47M | - | - | 20.90M | 34.75M | 62.07M | 60.74M | 30.90M | 3.70M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 80.48M | 94.10M | 121.71M | 104.72M | 90.54M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.79M | 20.46M | 21.77M | 19.29M | 15.86M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.12M | 17.02M | 43.44M | 29.04M | 18.74M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 705.00K | 5.04M | 11.93M | 12.07M | 4.24M | - |
| Net Income | -26.44M | -27.56M | -23.08M | -21.12M | -13.26M | -17.40M | -18.65M | -13.06M | -16.50M | 9.09M | -9.70M | -4.71M | -6.11M | -2.20M | 450.00K | 8.06M | 11.29M | 6.96M | 15.66M | 72.84M | 8.05M | -25.03M | -13.07M | -5.19M | 457.00K | -7.20M | -17.43M | 13.01M | 20.63M | 31.94M | 27.71M | 19.61M | - | - | 2.42M | 11.98M | 31.51M | 16.96M | 14.50M | -15.05M |
| Diluted EPS | - | - | - | - | - | - | -0.57 | -0.40 | -0.50 | 0.27 | -0.29 | -0.14 | -0.18 | - | 0.01 | 0.23 | 0.32 | 0.20 | 0.41 | 1.79 | 0.22 | -0.73 | -0.39 | -0.15 | 0.01 | -0.21 | -0.51 | 0.34 | 0.53 | 0.82 | 0.71 | 0.52 | - | - | 0.07 | 0.34 | 0.84 | 0.46 | 0.40 | -0.46 |
| R&D Expense | 3.25M | 3.33M | 2.13M | 2.18M | 2.07M | 2.19M | 2.27M | 2.24M | 1.91M | 2.25M | 2.99M | 2.46M | 2.49M | 2.40M | 2.67M | 2.49M | 2.14M | 2.47M | 2.93M | 3.46M | 1.45M | 1.61M | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.71M | 28.48M | 280.41M | 296.70M | 310.02M | 276.87M | 463.93M | 566.77M | 631.45M | 780.57M |
| Gross Profit | - | - | - | - | - | 114.74M | 103.04M | 179.84M | 150.62M | 209.49M | 326.17M | 377.34M | 463.26M |
| Operating Income | -16.04M | -17.66M | -26.91M | -94.08M | -75.45M | -20.68M | -23.75M | 56.23M | 17.63M | 33.32M | 166.96M | 169.90M | 179.64M |
| Net Income | -16.20M | -17.92M | -27.25M | -94.18M | -74.86M | -39.13M | -22.72M | 26.75M | 71.52M | -25.00M | 48.16M | 69.19M | 62.87M |
| Diluted EPS | - | - | - | - | - | -1.19 | -0.68 | 0.76 | 1.86 | -0.74 | 1.29 | 1.86 | 1.73 |
| R&D Expense | 14.16M | 14.96M | 7.97M | 14.95M | 8.57M | 8.66M | 10.34M | 9.77M | 9.45M | 3.98M | 0 | 0 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 5.09M | 97.72M | 162.02M | 135.57M | 291.25M | 306.30M | 643.84M | - | 1.17B | 1.14B | 1.66B | 1.66B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 419.99M | 537.60M | 482.26M | 691.41M |
| Cash & Equivalents | 11.94M | 7.55M | 1.63M | 95.70M | 153.22M | 118.70M | 146.63M | 170.02M | 174.12M | - | 173.69M | 238.95M | 70.56M | 231.25M |
| Inventory | - | - | - | - | - | - | - | - | - | - | 46.50M | 32.33M | 35.56M | 40.91M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 183.12M | 179.53M | 228.54M | 211.33M |
| Total Liabilities | - | - | 17.33M | 12.65M | 27.11M | 31.49M | 199.66M | 218.87M | 457.81M | - | 979.29M | 947.88M | 1.43B | 1.36B |
| Current Liabilities | - | - | 10.42M | 8.43M | 25.60M | 31.49M | 189.13M | 201.76M | 239.45M | - | 433.73M | 457.92M | 509.51M | 440.03M |
| Long Term Debt | - | - | - | - | 4.15M | - | 11.50M | 11.50M | - | - | 538.45M | 483.84M | 787.90M | 780.33M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 709.17M | 674.28M | 859.30M | 814.86M |
| Total Equity | -61.40M | -68.22M | -89.35M | 85.07M | 134.91M | 104.08M | 91.58M | 87.43M | 186.03M | - | 194.84M | 195.43M | 228.84M | 301.68M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 37.08M | 38.19M | 39.65M | 40.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -21.57M | -75.05M | -67.02M | 169.39M | 27.78M | 93.94M | 103.56M | 124.23M | 274.75M | 204.98M | 329.32M |
| Investing Cash Flow | - | - | -362.00K | -2.98M | -990.00K | -24.35M | -6.44M | -373.77M | -1.94M | -573.69M | -70.81M | -287.76M | -63.53M |
| Financing Cash Flow | - | - | 115.99M | 135.56M | 33.48M | -117.20M | 2.04M | 286.47M | -89.30M | 436.72M | -140.18M | -60.60M | -110.25M |
| Capital Expenditure | -206.00K | -8.00K | -362.00K | -477.00K | -990.00K | -5.48M | -6.44M | -5.55M | -1.94M | -1.62M | -461.00K | -1.65M | -1.74M |
| Free Cash Flow | - | - | -21.93M | -75.53M | -68.01M | 163.91M | 21.34M | 88.40M | 101.61M | 122.61M | 274.29M | 203.33M | 327.58M |
| Share Buybacks | - | - | - | - | - | - | - | - | 47.86M | 14.06M | 75.00M | 60.02M | 25.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 40.9% | 34.7% | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| Operating Margin % | - | - | - | -5,498.7% | -264.9% | -7.4% | -8.0% | 18.1% | 6.4% | 7.2% | 29.5% | 26.9% | 23.0% |
| Net Margin % | - | - | - | -5,504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
| ROE % | 23.7% | 20.1% | -32.0% | -69.8% | -71.9% | -42.7% | -26.0% | 14.4% | - | -12.8% | 24.6% | 30.2% | 20.8% |
| ROCE % | - | 331.6% | -30.1% | -69.0% | -72.5% | -20.3% | -22.7% | 13.9% | - | 4.5% | 24.4% | 14.7% | 14.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.71% | 5.44M | $137.93M |
| 2 | Jupiter Topco LLC | 6.60% | 2.15M | $54.43M |
| 3 | Invesco Ltd. | 5.78% | 1.88M | $47.72M |
| 4 | Fuller & Thaler Asset Management Inc. | 5.02% | 1.63M | $41.39M |
| 5 | Principal Financial Group, Inc. | 5.01% | 1.63M | $41.38M |
| 6 | State Street Corporation | 4.70% | 1.53M | $38.76M |
| 7 | Massachusetts Financial Services Co. | 4.32% | 1.41M | $35.63M |
| 8 | Vanguard Capital Management LLC | 4.24% | 1.38M | $35.01M |
| 9 | Renaissance Technologies, LLC | 4.20% | 1.37M | $34.64M |
| 10 | Eventide Asset Management LLC | 4.18% | 1.36M | $34.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COLL
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQOXZPQmFpNnpRWEJHVDZZX3FZN3AyRVpaX2RBd0o1NDFUU3kwbVRRVFI3VnRYc05FNXFieHU4dm8wQjlWZEx4RVdVZmJ3SkJyR2U1bml3ZEJRSkhGR2t4RDdkM191VnNHcFUwVm83TzJtX0FuT3ZsX1A0b0dLR1g1OWVjcktpMWo3aWdBTU…
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In Q3 - Benzinga
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPQ0ZGXzFZWnMyUXhHT05YWXpGWE5NbVhNMTY5cFp1VG0xRHNueUZ6UGpueUVJM2REdC1GQ3lGbWs5UkN6d0FVd3hDYUVUaVNrVVZiLW0waVFnblBONElxUy01ZUt4XzJUQ2lhU2djUWRPRGtwOElaS2JlOFdHSC1GSjcxU0hrd2wzN0NmT1…
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks - StockStory
<a href="https://news.google.com/rss/articles/CBMi_gFBVV95cUxOcGpDNlZVOXMxT2EwMThZV1U0blI2T29PNnFKOUw2M0dfeHdrd0ZBbnFIWGFEVkhGbk45WU1TT2Z5ZWFnak1reVh6ckZKUlI4TnpSYjBHV2dxV0pIQ0F0bTI5RVpfRXJ3X1p6NG4wdEItVlZLcGt0bUpLQmcwdFdMamFKMFdDM2dWaVFqdW…
Israel A. Englander reports new Collegium (NASDAQ: COLL) stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNTGkxVjBVN3NEV3A0T1NTcXdnMXIxRXp1bUNSTGZTYjdVbUpJQlRSZ0hHdm1FWVhGSVprejNmVEUyaVVya083eldnVnhVNFFYcXNhX2hHZ21IUWpXZmFhSkZaRWJiaW1pUXEzR2lvZnRLV05xYXdlOXRXWHJkbDl6clhJMlNGMGFNMDBwYk…
COLL - Collegium Pharmaceutical Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5DY0xEQmNZanRIQUtSZ1lrTTJEcHdDblBlX3hKc1hJVlVEMEU4VkhPSlNRYnlOVTJFM2dhV0VwY0lhN2tmRkE?oc=5" target="_blank">COLL - Collegium Pharmaceutical Inc Stock Price and Quote</a>  …
Collegium Pharmaceutical (COLL) Stock Revenue Growth Masks Deepening Margin Squeeze - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPSHN2QjBGOFBIVmxYUXM1YzhJLWtPR1hfSkotazhwamMzWHRkMzZjaklmN0dFcTVQdWo0NURZaThLNFhwVEJwNEQwMEZrUlU4Vk9vZXktU1M2dlZScjYwYWFZZ0RhRUJ3dDI3Rk5Bemp5SU9SYnFBa21FWUdVX0gtSXQtWXFwRUVQZlYwWn…
COLL — Frequently Asked Questions
What is the current share price of Collegium Pharmaceutical, Inc. (COLL)?
As of 2026-09-07 16:24 PDT, Collegium Pharmaceutical, Inc. (COLL) trades at $23.53 on NasdaqGS. Its 52-week range is $23.53 to $49.84.
What is the market capitalisation of COLL?
Collegium Pharmaceutical, Inc. (COLL) has a market capitalisation of $763.17M on NasdaqGS.
What is the P/E ratio of COLL?
COLL trades at a trailing price-to-earnings (P/E) ratio of 18.53. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.07.
What is the return on equity (ROE) of COLL?
COLL has a return on equity (ROE) of 17.61%. Its return on capital employed (ROCE) is 14.76%.
Is COLL a good stock to buy?
This page provides a data-driven analysis of Collegium Pharmaceutical, Inc. (COLL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.